Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Sironi
Maria
M
Bertola
Giorgio
G
Lodato
Antonio
A
Spinelli
Maurizio
M
Sciariada
Luca
L
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000473:pathology; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects*; D007947:Leukemia, Megakaryoblastic, Acute / Q000209:etiology* / Q000473:pathology; D008297:Male; D008533:Megakaryocytes / Q000473:pathology; D008875:Middle Aged; D010885:Pipobroman / Q000008:administration & dosage / Q000009:adverse effects*; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000188:drug therapy*; D013997:Time Factors
D010885:Pipobroman; D002066:Busulfan; D006918:Hydroxyurea